Search clinical trials for: Autologous CD19 CAR EGFTt T cells

Total 1031 results

Shanghai Changzheng Hospital

Recruiting

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

Systemic Sclerosis | Sjogren's Syndrome | Antiphospholipid Syndrome | ANCA Associated Vasculitis | Systemic Lupus Erythematosus (SLE) | Inflammatory Myopathy

China
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma (CD19-CARNK/T)

Mantle Cell Lymphoma (MCL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | Diffuse Large B Cell Lymphoma( DLBCL)
The First Affiliated Hospital of Nanchang University

Unknown

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

Acute Lymphoblastic Leukemia ,Lymphomas

China
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Verismo Therapeutics

Recruiting

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Ovarian Cancer | Mesothelioma, Malignant | Cholangiocarcinoma Recurrent

United States
City of Hope Medical Center
National Cancer Institute (NCI); Food and Drug Administration (FDA)

Active, not recruiting

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III Glioma

United States
Essen Biotech

Recruiting

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases (BAH247)

Autoimmune Diseases | Systemic Lupus Erythematosus | Sjogren's Syndrome | Systemic Lupus Erythematosus Acute

China
University of Pennsylvania

Not yet recruiting

Retreatment With CTL019/CTL119

Lymphoma, B-Cell

United States
Changhai Hospital

Recruiting

A Study of IMC008 for Advanced Solid Tumors

Advanced Solid Tumor

China
Seattle Children's Hospital

Active, not recruiting

A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma (PLAT-04)

Leukemia

United States
Seoul National University Hospital

Recruiting

Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia

Korea, Republic of
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Chongqing University... and other collaborators

Unknown

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

B Cell Leukemia | Relapsed Adult ALL

China
Juno Therapeutics, a Subsidiary of Celgene

Terminated

Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET)

Acute Lymphoblastic Leukemia

United States
Wenbin Qian
Zhejiang Provincial Tongde Hospital

Unknown

Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

B Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/22 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Hrain Biotechnology Co., Ltd.
Shanghai Zhongshan Hospital

Recruiting

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

Follicular Lymphoma | Diffuse Large B-cell Lymphoma | CD19-positive

China
John Lister
Miltenyi Biotec, Inc.; Lentigen Technology, Inc.; AHN (Allegheny Health Network)...

Recruiting

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | B Acute Lymphoblastic Leukemia | B-Cell Lymphoma | Transformed Lymphoma

United States
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

B-cell Leukemia

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditions

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/70 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
University of Pennsylvania

Completed

Autologous Redirected RNA Meso-CIR T Cells

Malignant Pleural Mesothelioma

United States
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; 920th Hospital of Joint Logistics Support... and other collaborators

Not yet recruiting

Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

Lymphoma, Non-Hodgkin

China
Shanghai Cell Therapy Group Co.,Ltd

Active, not recruiting

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

Non-Hodgkin Lymphoma, B-cell

China
Eden BioCell Ltd.
National Taiwan University Hospital

Terminated

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

Taiwan
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

B-cell Lymphoma

China
Beijing Tsinghua Chang Gung Hospital
China Immunotech Pharmaceuticals Co.Ltd.

Suspended

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

B-cell Non-Hodgkin's Lymphoma

China
Autolus Limited

Completed

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)

Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic Leukemia

United Kingdom
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Refractory | B-Cell Lymphoma Stage I | Relapsed

China
National Cancer Institute (NCI)

Completed

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-cell | Lymphoma, Hodgkins | Lymphoma, Non-hodgkins

United States
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; 920th Hospital of Joint Logistics Support... and other collaborators

Not yet recruiting

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

China
M.D. Anderson Cancer Center
Ziopharm Oncology

Terminated

CD19-Specific T Cells Post AlloSCT

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory B Acute Lymphoblastic Leukemia | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory... and other conditions

United States
CARsgen Therapeutics Co., Ltd.
Fudan University

Recruiting

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Pancreatic Cancer

China
Beijing Tiantan Hospital
Tasly Pharmaceutical Group Co., Ltd; Beijing Neurosurgical Institute

Recruiting

Tris-CAR-T Cell Therapy for Recurrent Glioblastoma

Recurrent Glioblastoma

China
Guangdong Provincial People's Hospital
Chinese Academy of Sciences; Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

Unknown

Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia

Acute Leukemia

China
Zhejiang University
Innovative Cellular Therapeutics Co., Ltd.

Unknown

CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma

Lymphoma

China
Chi Kong Li
Hong Kong Children's Hospital

Recruiting

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

Leukemia, Lymphocytic | Lymphoma, Nonhodgkin

China
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Hrain Biotechnology Co., Ltd.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Recruiting

Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia

Acute Lymphoblastic Leukemia | CD19-positive

China
Bambino Gesù Hospital and Research Institute

Active, not recruiting

Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL

CD19-ALL | CD19-LNH

Italy
RenJi Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

CD19-redirected Autologous Cells (CAR-CD19 T Cells)

CD19 Positive Malignant B-cell Leukemia and Lymphoma

China
Zhujiang Hospital
Guangdong Zhaotai Cell Bio-tech Co., LTD

Withdrawn

CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma (CAR19T2)

B-cell Acute Lymphoblastic Leukemia | B-Cell Lymphoma, Unspecified

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma

United States
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Lymphoma, B-Cell

China
Nanfang Hospital of Southern Medical University

Recruiting

CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia Not Having Achieved Remission

China
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (BAH241)

Lymphoma, Follicular | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, in Relapse | MCL | Central Nervous System Lymphoma | Acute Lymphoblastic Leukemia, Adult B-Cell | Non-Hodgkin Lymphoma, B-cell

China
Vinmec Research Institute of Stem Cell and Gene...
National Institute of Hematology and Blood Transfusion, Vietnam

Recruiting

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

B-Cell Non Hodgkin Lymphoma | B-Cell Acute Lymphoblastic Leukemia

Vietnam
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Tessa Therapeutics

Active, not recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (CERTAIN)

Anaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

United States

Search clinical trials for: Autologous CD19 CAR EGFTt T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations